Država: Kanada
Jezik: angleščina
Source: Health Canada
LATANOPROST
MINT PHARMACEUTICALS INC
S01EE01
LATANOPROST
50MCG
SOLUTION
LATANOPROST 50MCG
OPHTHALMIC
2.5ML
Prescription
PROSTAGLANDIN ANALOGS
Active ingredient group (AIG) number: 0132916002; AHFS:
APPROVED
2014-03-07
PRODUCT MONOGRAPH Pr MINT-LATANOPROST (Latanoprost Ophthalmic Solution) 50 mcg/mL PROSTAGLANDIN F 2Α ANALOGUE Mint Pharmaceuticals Inc., Date of Preparation: 1093 Meyerside Drive, Unit 1, February 14, 2014 Mississauga, Ontario L5T 1J6 CONTROL NO. 161370 Page 2 of 32 PRODUCT MONOGRAPH Pr MINT-LATANOPROST (Latanoprost Ophthalmic Solution) 50 mcg /mL Prostaglandin F 2α analogue ACTION AND CLINICAL PHARMACOLOGY MINT-LATANOPROST (latanoprost), a prostaglandin F 2α (13,14-dihydro-17-phenyl-18,19,20- trinor-PGF 2α isopropyl ester) analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure by increasing the outflow of aqueous humour. Studies in animals and man indicate that the main mechanism of action is increased uveoscleral outflow. Glaucoma is a disease with characteristic optic nerve damage and a corresponding visual field defect. Increased intraocular pressure (IOP) is one of the main risk factors. However, disturbances in blood flow may also play a role in some cases. In ocular hypertension, patients may have increased IOP but without changes in the visual field or corresponding optic nerve damage. MINT-LATANOPROST is a sterile, isotonic, buffered aqueous solution with a pH of approximately 6.7. Each mL contains 50 mcg of Latanoprost, a colourless to yellow oil. Latanoprost is an isopropyl ester prodrug which is well absorbed through the cornea and upon entering the aqueous humour is rapidly and completely hydrolysed to the biologically active acid. Studies in humans indicate that the peak concentration in the aqueous humour is reached about two hours after topical administration. Following topical administration in monkeys, latanoprost is primarily distributed in the anterior segment, conjunctiva and eyelids with only minute quantities reaching the posterior segment. Reduction of IOP following a single dose in humans starts about 3 to 4 hours following topical Page 3 of 32 administration, and the maximum effect is reached after 8 to 12 hours. Pressure reduction is maintaine Preberite celoten dokument